FULC News and Press, Fulcrum Therapeutics Inc. From 08/05/23

2023-08-05 05:18:06 ET Fulcrum Therapeutics, Inc. (FULC) Q2 2023 Earnings Conference Call August 03, 2023, 08:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alexander Sapir - President and Chief Executive Officer Iain Fraser - Interim Chief...

2023-08-03 10:18:52 ET Fulcrum Therapeutics press release ( NASDAQ: FULC ): Q2 GAAP EPS of -$0.38 beats by $0.06 . Collaboration revenue of $0.9M (-52.6% Y/Y) misses by $0.06M . As of June 30, 2023, cash, cash equivalents, and marketable securities we...

2023-08-03 09:25:02 ET Clinical-stage biopharmaceutical company Fulcrum Therapeutics ( NASDAQ: FULC ) announced the appointment of Alan A. Musso as its chief financial officer, effective August 7. Before joining Fulcrum, Alan served for several years as chief financial officer...

― Screening closed for the Phase 3 REACH pivotal trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) ― ― Expect to report topline data for REACH in the fourth quarter of 2024 ― ― Interactions continue with the U.S. Food and Dru...

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief...

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second qua...

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has entered into a worldwide, exclusi...

RANDOLPH, Mass. and CAMBRIDGE, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics (Nasdaq: FULC) announce the launch of Project Mercury, a first-of-its-kind collaboration of global stakeholders committed to identifying and addressing the ch...

2023-05-24 14:15:54 ET Summary Crisis of confidence in prior management (related to full clinical hold in February for FTX-6058 in SCD) led to currently cheap valuation. New CEO (appointed mid May) sold prior companies to Pfizer and Sobi. Primary endpoint for losmapimod in FSH...

2023-05-15 10:19:06 ET Fulcrum Therapeutics, Inc. (FULC) Q1 2023 Earnings Conference Call May 15, 2023 08:00 A.M. ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Robert J. Gould - President and CEO Iain Fraser - Interim Chief Medical Officer ...